BofA analyst Alec Stranahan lowered the firm’s price target on Day One Biopharmaceuticals (DAWN) to $21 from $24 and keeps a Buy rating on the shares. While Q1 earnings season will focus on commercial launches for the analyst’s small to mid cap biotech coverage, conversation around pharma tariffs, tax impact, and FDA turnover “should provide an additional overlay to sentiment,” the analyst tells investors in a preview for the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Promising Outlook for Day One Biopharmaceuticals: Buy Rating Driven by Ojemda’s Market Potential
- Buy Rating for Day One Biopharmaceuticals: Strong Financial Position and Strategic Growth Potential
- Day One Biopharmaceuticals price target lowered to $34 from $39 at JPMorgan
- Day One Biopharma’s Earnings Call Highlights Growth and Challenges
- Day One price target lowered to $30 from $34 at JonesResearch